Great Lakes Advisors LLC Takes $3.81 Million Position in Roivant Sciences Ltd. $ROIV

Great Lakes Advisors LLC acquired a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the second quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 107,786 shares of the company’s stock, valued at approximately $3,815,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its holdings in Roivant Sciences by 15.4% during the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Roivant Sciences by 1.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock worth $24,678,000 after buying an additional 34,341 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Roivant Sciences by 1.9% in the second quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock worth $1,010,000 after buying an additional 1,689 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Roivant Sciences by 149.9% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares during the period. Finally, M&T Bank Corp boosted its holdings in shares of Roivant Sciences by 10.2% during the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the period. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ROIV has been the topic of several recent analyst reports. Sanford C. Bernstein upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Wednesday, July 29th. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings downgraded Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Guggenheim lifted their price objective on Roivant Sciences from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Finally, Bank of America reissued a “neutral” rating on shares of Roivant Sciences in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $35.14.

Insider Buying and Selling at Roivant Sciences

In other news, insider Mayukh Sukhatme sold 284,707 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the completion of the transaction, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This represents a 1.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Melissa B. Epperly sold 17,750 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $34.38, for a total value of $610,245.00. Following the completion of the transaction, the director directly owned 16,474 shares of the company’s stock, valued at approximately $566,376.12. The trade was a 51.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 2,520,739 shares of company stock worth $87,746,445 in the last three months. 8.80% of the stock is currently owned by company insiders.

Roivant Sciences Trading Down 1.5%

Shares of ROIV stock opened at $36.84 on Friday. The firm has a market capitalization of $26.61 billion, a P/E ratio of -69.51 and a beta of 1.12. Roivant Sciences Ltd. has a 1 year low of $11.54 and a 1 year high of $37.97. The firm’s fifty day simple moving average is $34.48 and its 200 day simple moving average is $30.38.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $2.06 million. Equities research analysts anticipate that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.